Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
C$1.43
-2.1%
C$1.44
C$1.20
C$4.49
C$107.85M1.4978,062 shs22,910 shs
Veresen Inc stock logo
VSN
Veresen
C$18.51
-2.3%
C$18.51
C$11.40
C$19.07
C$5.81BN/A1.30 million shs1.15 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%-73.83%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
+1.39%0.00%+5.80%-11.52%-8.75%
Veresen Inc stock logo
VSN
Veresen
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.7131 of 5 stars
3.50.00.00.00.01.70.0
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
0.646 of 5 stars
3.50.00.00.01.30.00.0
Veresen Inc stock logo
VSN
Veresen
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.75∞ Upside
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
3.00
BuyC$6.00319.58% Upside
Veresen Inc stock logo
VSN
Veresen
N/AN/AN/AN/A

Current Analyst Ratings

Latest MDNA, DDDD, ONC, VSN, and TILS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperformC$3.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AC$0.34 per share4.22C$0.37 per shareN/A
Veresen Inc stock logo
VSN
Veresen
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$27.75M-C$0.41N/AN/AN/A-102.66%-55.47%5/3/2024 (Estimated)
Veresen Inc stock logo
VSN
Veresen
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MDNA, DDDD, ONC, VSN, and TILS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$0.15-C$0.05+C$0.10-C$0.05N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AN/AN/AN/A
Veresen Inc stock logo
VSN
Veresen
C$1.005.40%N/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
1.54
9.01
8.86
Veresen Inc stock logo
VSN
Veresen
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
6.98%
Veresen Inc stock logo
VSN
Veresen
N/A

Insider Ownership

CompanyInsider Ownership
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
6.24%
Veresen Inc stock logo
VSN
Veresen
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
2975.42 millionN/ANot Optionable
Veresen Inc stock logo
VSN
Veresen
147,000314.00 millionN/ANot Optionable

MDNA, DDDD, ONC, VSN, and TILS Headlines

SourceHeadline
Veresen (TSE:VSN) Shares Pass Above Two Hundred Day Moving Average of $0.00Veresen (TSE:VSN) Shares Pass Above Two Hundred Day Moving Average of $0.00
americanbankingnews.com - April 23 at 3:22 AM
Jordan Cove parent company looks at financing, ownership options, expansionJordan Cove parent company looks at financing, ownership options, expansion
theworldlink.com - September 28 at 10:38 PM
ELD apologises after nearly 10,000 voters in Tanjong Pagar GRC receive two poll cards due to printer’s errorELD apologises after nearly 10,000 voters in Tanjong Pagar GRC receive two poll cards due to printer’s error
channelnewsasia.com - August 27 at 8:05 AM
Jordan Cove donates more than $300,000 to defeat measureJordan Cove donates more than $300,000 to defeat measure
theworldlink.com - May 22 at 9:08 AM
Encuentran al menos 60 cadáveres en provincia del Congo - ChronEncuentran al menos 60 cadáveres en provincia del Congo - Chron
news.google.com - April 26 at 3:31 PM
Veresen (TSE:VSN) Stock Price Passes Above Two Hundred Day ... - Defense WorldVeresen (TSE:VSN) Stock Price Passes Above Two Hundred Day ... - Defense World
news.google.com - April 18 at 8:35 AM
Oregon DEQ opens comments on permit renewal for former Weyerhaeuser facilityOregon DEQ opens comments on permit renewal for former Weyerhaeuser facility
theworldlink.com - April 11 at 5:09 PM
Bidders Can Structure Offers To Discourage The Use Of Rights Of ... - Mondaq News AlertsBidders Can Structure Offers To Discourage The Use Of Rights Of ... - Mondaq News Alerts
news.google.com - April 5 at 8:22 AM
Recuperan 36 cadáveres en un pozo tras derrumbe en India - Hartford City News TimesRecuperan 36 cadáveres en un pozo tras derrumbe en India - Hartford City News Times
news.google.com - March 31 at 10:30 PM
The Right Of First Refusal And Good Faith In Your Business Contract ... - Mondaq News AlertsThe Right Of First Refusal And Good Faith In Your Business Contract ... - Mondaq News Alerts
news.google.com - March 29 at 10:05 AM
Bidders can Structure Offers to Discourage the Use of Rights of First ... - LexologyBidders can Structure Offers to Discourage the Use of Rights of First ... - Lexology
news.google.com - March 28 at 7:52 AM
Pembina Pipeline : Gas Infrastructure - Marketscreener.comPembina Pipeline : Gas Infrastructure - Marketscreener.com
news.google.com - March 27 at 3:55 PM
Bidders can Structure Offers to Discourage the Use of Rights of First ... - McMillan LLPBidders can Structure Offers to Discourage the Use of Rights of First ... - McMillan LLP
news.google.com - March 27 at 3:55 PM
BBC Sounds - Assignment - Available EpisodesBBC Sounds - Assignment - Available Episodes
bbc.co.uk - March 25 at 8:34 PM
The Right of First Refusal and Good Faith in Your Business Contract ... - LexologyThe Right of First Refusal and Good Faith in Your Business Contract ... - Lexology
news.google.com - March 21 at 3:02 PM
Liquefied Natural Gas Market to See Massive Growth by 2029 ... - Digital JournalLiquefied Natural Gas Market to See Massive Growth by 2029 ... - Digital Journal
news.google.com - March 14 at 7:23 PM
Natural Gas Market Booming Worldwide( Forecast Period 2023-2029) With Top Player:BG Group plc, Apache Corporat - openPRNatural Gas Market Booming Worldwide( Forecast Period 2023-2029) With Top Player:BG Group plc, Apache Corporat - openPR
news.google.com - March 14 at 7:23 PM
Long-term supply agreements and high inflation — what businesses ... - McCarthy Tétrault LLPLong-term supply agreements and high inflation — what businesses ... - McCarthy Tétrault LLP
news.google.com - March 9 at 9:20 AM
CEN: Reasonable CEF, But The Private Position Could Be A ... - Seeking AlphaCEN: Reasonable CEF, But The Private Position Could Be A ... - Seeking Alpha
news.google.com - March 8 at 5:49 PM
Insights and Takeaways From Our Top 10 Commercial Litigation ... - LexologyInsights and Takeaways From Our Top 10 Commercial Litigation ... - Lexology
news.google.com - February 28 at 7:14 AM
Global Natural Gas Market Industry Analysis, Size, Share, Demand ... - Taiwan NewsGlobal Natural Gas Market Industry Analysis, Size, Share, Demand ... - Taiwan News
news.google.com - February 27 at 9:13 PM
Hallan 18 cadáveres en Bulgaria; serían presuntos migrantes - ChronHallan 18 cadáveres en Bulgaria; serían presuntos migrantes - Chron
news.google.com - February 17 at 3:48 PM
Mueren ahogadas 14 personas en accidente vial en México - ChronMueren ahogadas 14 personas en accidente vial en México - Chron
news.google.com - February 8 at 11:35 PM
Can A Bidder Structure An Offer To Discourage The Exercise Of A ... - MondaqCan A Bidder Structure An Offer To Discourage The Exercise Of A ... - Mondaq
news.google.com - February 8 at 6:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Medicenna Therapeutics logo

Medicenna Therapeutics

NASDAQ:MDNA
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Oncolytics Biotech logo

Oncolytics Biotech

TSE:ONC
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Veresen logo

Veresen

TSE:VSN
Veresen Inc is a Canada-based energy infrastructure company that owns and operates energy infrastructure assets across North America. The Company is engaged in three principal businesses: a pipeline transportation business consists of interests in the Alliance Pipeline, the Ruby Pipeline and the Alberta Ethane Gathering System (AEGS); a midstream business, which includes a partnership interest in Veresen Midstream Limited Partnership, which owns assets in western Canada, and an ownership interest in Aux Sable, which owns a natural gas liquids (NGL) extraction facility near Chicago, and other natural gas and NGL processing energy infrastructure, and a power business consists of a portfolio of assets in Canada. The Company's segments include Pipelines, Midstream, Power and Corporate. Alliance Pipeline owns and manages an integrated, high-pressure natural gas and NGL pipeline. Ruby Pipeline is a natural gas transmission system. AEGS is an integrated pipeline system.